Immatics is developing targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER™). Immatics’ wholly owned pipeline is comprised of eight therapeutic programs, of which four are in clinical trials and four are in preclinical development.
Each therapeutic modality is designed with distinct attributes to produce the desired therapeutic effect for patients at different disease stages and with different types of tumors:
- Adoptive Cell Therapy: Immatics’ clinical product class ACTengine® is a personalized approach in which the patient’s own T cells are genetically modified to express a novel proprietary TCR cognate to one of Immatics’ cancer targets and are then reinfused. This approach is also known as TCR-T (T cell receptor T cell). The product class ACTallo® is advancing the ACT concept beyond individualized manufacturing and is being developed to generate “off-the-shelf” cellular therapy. ACTolog® is a clinical Pilot study for ultra-personalized, multi-target immunotherapy utilizing endogenous (non-genetically engineered) T cells with the goal of paving the way for a next step of enabling a fully engineered multi-TCR-T.
- TCR Bispecifics (TCER™) are engineered “off-the-shelf” biologics consisting of a portion of the TCR which directly recognizes cancer cells and a T cell recruiter domain which recruits and activates the patient’s T cells. TCER™ are designed to attract any patient’s circulating T cells to bind and come into direct proximity with the cancer cells in order to destroy the cancer.
In addition to this proprietary pipeline, Immatics is also developing some of its targets and TCRs through programs in alliances with global leaders, such as Amgen, Genmab, Bristol Myers Squibb and GlaxoSmithKline. In these partnerships, Immatics seeks to evaluate and develop ten partnered programs based on novel Immatics-derived targets in a variety of immunotherapeutic approaches.
From its research and development origins in Tübingen, Germany, to its cell therapy center in Houston, Texas, Immatics’ global team is committed to developing and advancing its therapeutic pipeline and collaboration programs to address significant unmet medical needs in oncology.